WO2011145808A3 - 클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물 - Google Patents

클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물 Download PDF

Info

Publication number
WO2011145808A3
WO2011145808A3 PCT/KR2011/002747 KR2011002747W WO2011145808A3 WO 2011145808 A3 WO2011145808 A3 WO 2011145808A3 KR 2011002747 W KR2011002747 W KR 2011002747W WO 2011145808 A3 WO2011145808 A3 WO 2011145808A3
Authority
WO
WIPO (PCT)
Prior art keywords
clevudine
composition
chronic hepatitis
treating chronic
adefovir dipivoxil
Prior art date
Application number
PCT/KR2011/002747
Other languages
English (en)
French (fr)
Other versions
WO2011145808A2 (ko
Inventor
이성구
이영춘
Original Assignee
부광약품 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020100046543A external-priority patent/KR20100127180A/ko
Application filed by 부광약품 주식회사 filed Critical 부광약품 주식회사
Priority to CN201180024843XA priority Critical patent/CN102917706A/zh
Priority to US13/697,667 priority patent/US20130059812A1/en
Priority to SG2012083465A priority patent/SG185545A1/en
Publication of WO2011145808A2 publication Critical patent/WO2011145808A2/ko
Publication of WO2011145808A3 publication Critical patent/WO2011145808A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 클레부딘(Clevudine) 및 아데포비어 디피복실(Adefovir dipivoxil)을 포함하는 만성 B형 간염 치료용 조성물에 관한 것으로, 본 발명의 복합제는 단일 성분 제제에 비하여 B형 간염 바이러스 감염증 치료 효과의 극대화 및 내성 바이러스에 대한 상호 억제작용 나타낸다.
PCT/KR2011/002747 2009-05-25 2011-04-18 클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물 WO2011145808A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201180024843XA CN102917706A (zh) 2010-05-18 2011-04-18 含有克拉夫定及阿德福韦酯的用于治疗慢性乙型肝炎的组合物
US13/697,667 US20130059812A1 (en) 2009-05-25 2011-04-18 Composition for treating chronic hepatitis b, containing clevudine and adefovir dipivoxil
SG2012083465A SG185545A1 (en) 2010-05-18 2011-04-18 Composition for treating chronic hepatitis b, containing clevudine and adefovir dipivoxil

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100046543A KR20100127180A (ko) 2009-05-25 2010-05-18 클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물
KR10-2010-0046543 2010-05-18

Publications (2)

Publication Number Publication Date
WO2011145808A2 WO2011145808A2 (ko) 2011-11-24
WO2011145808A3 true WO2011145808A3 (ko) 2012-02-23

Family

ID=44993236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002747 WO2011145808A2 (ko) 2009-05-25 2011-04-18 클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물

Country Status (3)

Country Link
CN (1) CN102917706A (ko)
SG (1) SG185545A1 (ko)
WO (1) WO2011145808A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116473974A (zh) * 2021-06-07 2023-07-25 天津济坤医药科技有限公司 杜伟利布在制备治疗特发性肺纤维化的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158150A1 (en) * 1998-11-02 2003-08-21 Triangle Pharmaceuticals, Inc. Combination therapy to treat hepatitis B virus
US20050196379A1 (en) * 2002-07-15 2005-09-08 Furman Philip A. Combination therapies with L-FMAU for the treatment of hepatitis B virus infection
US20090169504A1 (en) * 2006-12-28 2009-07-02 Idenix Pharmaceuticals, Inc Compounds and Pharmaceutical compositions for the treatment of Viral infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158150A1 (en) * 1998-11-02 2003-08-21 Triangle Pharmaceuticals, Inc. Combination therapy to treat hepatitis B virus
US20050196379A1 (en) * 2002-07-15 2005-09-08 Furman Philip A. Combination therapies with L-FMAU for the treatment of hepatitis B virus infection
US20090169504A1 (en) * 2006-12-28 2009-07-02 Idenix Pharmaceuticals, Inc Compounds and Pharmaceutical compositions for the treatment of Viral infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E. D. CLERCQ: "Perspectives for the treatment of hepatitis B virus infections", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 12, 1999, pages 81 - 95 *
IM , HYEONG JUN: "Management of Antiviral-Resistant Chronic Hepatitis B Virus Infection", JOURNAL OF THE KOREAN SOCIETY OF GASTROENTEROLOGY, vol. 51, 2008, pages 346 - 359 *
M.-N. BRUNELLE ET AL.: "Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir", HEPATOLOGY., vol. 41, 2005, pages 1391 - 1398 *

Also Published As

Publication number Publication date
CN102917706A (zh) 2013-02-06
SG185545A1 (en) 2012-12-28
WO2011145808A2 (ko) 2011-11-24

Similar Documents

Publication Publication Date Title
PH12014501314A1 (en) Hepatitis b antiviral agents
NO2020012I1 (no) Osilodrostat eller et farmasøytisk akseptabelt salt derav, inkludert osilodrostat dihydrogenfosfat
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
PH12014501702A1 (en) Imidazopyrrolidinone compounds
EP2669289A4 (en) QUINOLINE-LIKE COMPOUND CONTAINING A PHOSPHORUS-SUBSTITUTED GROUP, PREPARATION METHOD, MEDICAL COMPOSITION CONTAINING THE COMPOUND, AND APPLICATION
WO2010028015A3 (en) 2-oxo-1,2-dihydro-quinoline modulators of immune function
EA201301320A1 (ru) 4-арил-n-фенил-1,3,5-триазин-2-амины, которые содержат сульфоксиминную группу
AU2012324805A8 (en) (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
MD4602B1 (ro) Inhibitori ai virusului hepatic C
WO2012046030A3 (en) Phosphodiesterase inhibitors
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
WO2013173759A3 (en) Macrocyclic nucleoside phosphoramidate derivatives
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
PH12014502551B1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
WO2013128379A3 (en) Crystalline polymorphic forms of linagliptin
WO2012162578A3 (en) Anti-viral compounds
WO2015023508A3 (en) Methods for improving asthma symptoms using benralizumab
WO2011160043A3 (en) Pla2g16 as a target for antiviral compounds
WO2012040164A3 (en) Tlr5 ligands, therapeutic methods, and compositions related thereto
WO2011145808A3 (ko) 클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물
WO2010059639A3 (en) Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
WO2009128964A3 (en) Ensemble-based virtual screening reveals novel antiviral compounds for avian influenza neuraminidase
WO2013165898A3 (en) Compositions and methods for inhibiting resolvases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180024843.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 12012502210

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 13697667

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 9695/CHENP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1201005970

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11783690

Country of ref document: EP

Kind code of ref document: A2